Cytogenetic Characterization in AML: How Do Gene Mutations Impact Overall Treatment Outcomes?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Palliative & Supportive Care
Basic Science
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Lung
Business
Event

Playback speed

10 seconds

Cytogenetic Characterization in AML: How Do Gene Mutations Impact Overall Treatment Outcomes?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Mehmet Yilmaz

132 views

January 18, 2021

Comments 0

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Leukemia

Pre-Pandemic CML Treatment: What Is CGA? How Do Ponatinib, Nilotinib…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

P. Raanani

15 views

Challenges in Treatment of Leukemias and Bone Marrow Failure in Deve…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

K. Rashid

15 views

AML Treatment in Developing Countries: LIMC vs. HIC Differences - St…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Rego

13 views

Cytogenetic Characterization in AML: How Do Gene Mutations Impact Ov…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Yilmaz

132 views

Targeted Therapy for Older Patients With AML: Is Addition of GO to I…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

C. Schiffer

38 views

State of the Art in Adults With ALL: Salvage & 1L Ino and Blina + Ch…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Jabbour

23 views

How I Manage CML at MD Anderson in 2020: Are 1L Therapies Getting Be…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Jabbour

33 views

Pediatric ALL Updates: What Is the COG Risk Stratification Approach?…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

S. Anak

11 views

ALL Highlights: Should We De-Escalate Chemo? Do TKIs (Dasatinib, Nil…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

D. Hoelzer

13 views

Ph+ and Ph-Like Adult Frontline ALL: What Is the Optimal Strategy in…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

R. Foa

21 views

CAR-T in Pediatric ALL: Tisagenlecleucel in B-Cell Disease, CAR-T vs…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

F. Saglio

16 views

CML Highlights: Has Molecular Monitoring Replaced Cytogenetic Monito…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

R. Hehlmann

17 views

Molecular Monitoring and CML: What Is the Influence on Therapy and H…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

N. Chaudhri

13 views

Recommendations for Treatment Discontinuation in CML: Is TFR Feasibl…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

C. Fava

13 views

CML Updates: Prognostic Factors, Conventional Drugs, 1L Therapy, Tre…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

W. Sattar

15 views

19 y/o Male With Jaundice and a Duodenal Ampulla Tumor: Does Standar…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Merter

11 views

AML Updates: Can CC-486 Improve OS in 1st Remission in Older Patient…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

G. Garcia-Manero

123 views

AML Highlights: Do Gilteritinib & Quizartinib Prolong OS in FLT3-Mut…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

G. Martinelli

57 views